Insider Buying: Oncolytics Biotech (TSE:ONC) Director Buys C$68,400.00 in Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Bernd Robert Seizinger purchased 60,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were acquired at an average price of C$1.14 per share, for a total transaction of C$68,400.00. Following the purchase, the director owned 526,991 shares in the company, valued at C$600,769.74. The trade was a 12.85% increase in their ownership of the stock.

Bernd Robert Seizinger also recently made the following trade(s):

• On Thursday, February 12th, Bernd Robert Seizinger acquired 40,000 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of C$1.17 per share, with a total value of C$46,800.00.

Oncolytics Biotech Trading Down 1.3%

Oncolytics Biotech stock opened at C$14.90 on Monday. Oncolytics Biotech Inc. has a one year low of C$0.44 and a one year high of C$2.08. The company’s fifty day moving average price is C$14.90 and its two-hundred day moving average price is C$13.19. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The company has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.